OBJECTIVES I-131 therapy for differentiated thyroid cancer (DTC) could induce adverse effects. The purpose of this study was to report and analyze symptoms after I-131 treatment within the hospitalization and present relevant medical intervention. METHODS I-131 doses ranging from 3.7 to 9.25 GBq (100-250 mCi) were administrated for thyroid remnant ablation or treating DTC metastases. 117 pati...

BACKGROUND Little is known about the whole body oxidative stress burden following radioactive iodine ((131)I) therapy of thyroid diseases. METHODS We studied 17 patients with benign nodular goiter treated with (131)I therapy. The targeted thyroid dose was 50 Gy in 11 patients pretreated with 0.1 mg of recombinant human TSH (rhTSH). In 6 patients, the applied thyroid dose was 100 Gy without rh...

BACKGROUND Iodine-131 ((131)I) is a well-established method for the treatment of hyperthyroidism. Following such therapy, patients may experience symptoms relating to early or delayed side effects that can be prevented or minimized if necessary measures are taken. We have noticed an unusual side effect of (131)I therapy in the form of a skin eruption (iododerma) and aimed at assessing the frequ...

CONTEXT Data from a large cohort of patients with pulmonary metastases from differentiated thyroid cancer (DTC) were retrospectively analyzed. OBJECTIVE To assess the effect of radioiodine therapy and investigate the prognostic factors of survival for patients with pulmonary metastasis secondary to DTC. METHODS A total of 372 patients with pulmonary metastasis from DTC treated with (131)I e...

The primary treatment of thyroid carcinoma is surgery and the outcome depends on its extent. The post-operative management alternatives in thyroid carcinoma include thyroid hormone, radio-iodine ablation (I-131 Na), external beam radiation therapy (EBRT) and occasionally adjuvant chemotherapy. This retrospective study analyzes the managements of 153 patients (102, 51), age range 10-96 yea...

We examined the merits of combinatorial hMUC1 vaccination and hNIS radioiodine gene therapy and evaluated its tumoricidal effects in an animal tumor model. CMNF (CT26 expressing hMUC1, hNIS, and firefly luciferase) cells were transplanted into 28 mice, and 4 and 11 days after tumor challenge, tumor-bearing mice were immunized i.m. with pcDNA3.1 or pcDNA-hMUC1 vaccine and subsequently administer...

UNLABELLED This aim of this retrospective study was to determine the impact of glucocorticoid therapy on the effective (131)I half-life in radioiodine therapy for Graves disease. METHODS Three hundred fifteen consecutive Graves disease patients undergoing radioiodine therapy at our institution between August 2004 and January 2009 were enrolled. We investigated the influences of thyroid state ...

OBJECTIVE It is sometimes difficult to assess I-131 lung uptake at the initial I-131 therapy because of strong artifacts from I-131 uptake in the thyroid bed. The aim of this study was to analyze the lung uptake at the second I-131 therapy for lung metastasis in patients who did not have lung uptake at the initial therapy from differentiated thyroid carcinoma (DTC). Then, we also analyzed the r...

BACKGROUND The aim of the study was to achieve an effective target dose in the thyroid by increasing the effective half-life (Teff) of (131)I by use of iodide ((127)I) two days after (131)I therapy in patients with hyperthyroidism with low Teff. MATERIAL AND METHODS The study was carried out in two groups. Group A - 41 patients, and Group B - 14 patients, all the patients were with hyperthyro...